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A B S T R A C T
Over a quarter of the individuals diagnosed with tuberculosis [TB] in the European Union region are born
outside of the area and the proportion has been increasing steadily. Italy is a low TB incidence country
with over 50% of TB cases in the foreign-born population primarily due to the high numbers of migrants
entering the country via land or sea. As a case study to evaluate the value of screening in newly arrived
migrants, the EDETECT-TB project in Italy implemented and evaluated active TB screening in the migrant
population at first reception centres to ensure early diagnosis to avoid further spread. Based on a cost-
effectiveness analysis from a program provider perspective, a decision tree model allowed the
assessment of the value for money of case finding by estimating the cost per case of active TB detected
compared with the status quo of no screening. The analysis confirmed that early case detection is a cost-
effective intervention in areas with migrants arriving from high TB risk settings. Targeted post-arrival
early screening of high TB risk vulnerable new entrants to Italy has a potential role in reducing the spread
of TB among migrants.
© 2021 Published by Elsevier Ltd on behalf of International Society for Infectious Diseases. This is an open
access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Introduction
Tuberculosis [TB] remains a major public health issue in
European Union (EU) compounded by the emergence of multi-
drug-resistant (MDR) and extensively drug-resistant (XDR) strains
(Aldridge et al., 2014; MacPherson and Gushulak, 2006). While
three-quarters of TB cases in the EU were born in European
countries, low incidence in some European countries is likely the
results of a decreasing trend started on centuries ago that was
parallel to the improvement of social and economic conditions,
while some studies also argue a lower susceptibility due to genetic
predisposition of part of the population (Cai et al., 2019). Thus, new
entrants now constitute a high and increasing proportion of
patients (D’Ambrosio et al., 2017). In 2019, there were 128,536 new
arrivals including refugees and migrants including from high
burden TB countries, who arrived by land or sea to Europe
primarily via Spain, Italy, Greece, Malta and Cyprus (Ardittis and
Laczk, 2020). Hence, coordinated effective and sustainable
interventions for prevention, diagnosis, and treatment are essen-
tial in the EU. A 2015 survey completed by all EU/EEA countries of
the WHO European Region, plus six additional EU candidate
countries (Albania, Bosnia and Herzegovina, the former Yugoslav
Republic of Macedonia, Montenegro, Serbia, and Turkey) showed
that 19 (52.8%) systematically screen migrants for latent TB
infection (LTBI), whereas 9/36 (25%) do not or 8/36 (22.2%) do not
systematically (Klinkenberg et al., 2009). Approaches imple-
mented to date include chest x-ray for active disease and
tuberculin skin, and interferon gamma release assay for latent
TB with varying degrees of success (Kunst et al., 2017). Further-
more, many vulnerable migrants who lack access to health care are
quite often not incorporated in the screening programmes. After
arrival, screening may provide a population level benefit by
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In this line, EU countries have focused on two major areas;
etecting prevalent TB cases in migrants to limit the onward
ransmission, and in some countries testing for, and treating LTBI in
igrants from high-TB burden countries to avoid reactivation
Kunst et al., 2017). However, the standards for testing migrants
ary across the EU with limited data on their comparative
fficiency (Greenaway et al., 2018) especially in the context of
creening new arrivals from high burden countries in the southern
order of the EU. Two studies have recently evaluated the
creening of migrants on arrival to countries on the southern
order of the EU over the last decade. One study (Pasta et al., 2019)
nvestigated migrants arriving in Lampedusa (Italy) from 2011 to
019. Of the 775 patients hospitalised, 167 were for infectious
iseases, 21 of whom were TB positive. Another study (Bertoncello
t al., 2018) estimated LTBI prevalence in migrant arriving by
editerranean Sea in 2016. Prevalence rates varied from 25-40%
ccording to tuberculin skin test and interferon-gamma assay
alues. Here we present a case study using data from the E-DETECT
B project (Barcellini et al., 2019) to illustrate the cost effectiveness
f screening.
ost effectiveness of screening migrants in Italy
The EDETECT-TB project aims to contribute to the ultimate
limination of tuberculosis in the EU by utilising evidenced based
nterventions to ensure early diagnosis, improve integrated care
nd support community and prison outreach activities in low and
igh-incidence countries. In Italy, the project implemented and
valuated active TB screening in hard-to-reach populations, i.e. the
efugee population at first reception centres to ensure early
iagnosis, improve integrated care and support the community to
void further spread (Abubakar et al., 2018). We utilised data from
he E-DETECT TB project to assess the cost-effective of early
etection from a provider perspective by estimating the cost per
ase of active TB screening method on migrants landing in Sicilian
orts. In Italy, amongst over 3,000 cases of TB are diagnosed
annually; over 50% occur in the foreign-born population coming
from countries with an estimated TB incidence above 150/100,000
(Fattorini et al., 2016). 70% of the total migrants and refugees who
arrived in Europe in 2017 landed in Italy according to the
International Organization for Migration (IOM) (Ardittis and Laczk,
2020). Italy is a low TB incidence country and most of XDR and
MDR TB cases (81%), which are more difficult to treat than drug-
susceptible TB due to the limited and potentially toxic treatment
options, occur in the migrant population (Lönnroth et al., 2015;
Odone et al., 2011; Blasi et al., 2017). Departing mainly from Libya,
newly arrived individuals either claim asylum or pass through Italy
to move to other countries of the EU (Hamood, 2006). Once in Italy,
refugees are firstly hosted in specific hotspots and, after few days,
transferred to regional first-line reception centres (hubs) (Gian-
netto et al., 2019). In hotspots, active case-finding is based on TB
symptoms screening, while in first aid reception centres inter-
ventions are often limited to passive case finding. In the latter, case
findings are performed in symptomatic migrants who report
themselves to health centres or who visit outpatient clinics for
unrelated medical conditions. Case-finding is performed regard-
less of the vaccination status of the individual, which is usually
unknown. Furthermore, nationwide data on TB in asylum seekers
is limited mostly because of the health system that is fragmented
on a regional level and due to the different approaches regarding
TB testing/notification that are adopted by each region and-or
healthcare facility (Campomori and Ambrosini, 2020). Active case
finding for TB is a key element of the World Health Organization
(WHO), European, and Italian general recommendations to tackle
down TB (World Health Organization, 2013).
As part of the EDETECT program, newly landed migrants in
Sicily were screened for active TB (between November 2016 and
December 2017) using a smartphone application (standardised E-
questionnaire was carried out by medical staff), followed in
symptomatic individuals by fast molecular test (Xpert MTB/RIF
Ultra) on collected sputum samples (Barcellini et al., 2019).
Asylum seekers (n = 3,787) in first line reception centres were
interviewed through the use of the E-Detect App to collect
demographic and clinical data. The app was also used to collect
able 1
puts of the cost-effectiveness analysis: costs and probabilities.
Costs per sample and salaries per activity duration
Activity (Staff costs)a Average time (minutes) Average hourly rates (s)
Nurse assistants presenting/administering the questionnaire 5 minutes 13.04
Nurse collecting sputum sample 10 minutes 14.02
Medical doctor clinical evaluation of positive/information 30 minutes 35.90
Activity (costs of transportation) Average number of samples Average rate per trip (s)
Courier charges from Sicily to the main lab in Milan 60 per trip 50.00
Testb Cost per test (s)
XpertMTB/RIF Ultra 58.91
Model parameters
Parameter Probability (uncertainty) Source/Reference
Presence of TB symptoms 0.24 EDETECT study
Xpert MTB/RIF sensitivity 0.85
(95% CI: 0.82–0.88)
Li et al. (2017)
Xpert MTB/RIF specificity 0.98
(95% CI: 0.96–0.98)
Li et al. (2017)Offer and acceptance to TB screening if symptomatic 0.63 EDETECT study
Offer and acceptance to TB screening if asymptomatic 0.01 EDETECT study
TB positive in symptomatic screened 0.03 EDETECT study
TB positive in asymptomatic screened 0.11 EDETECT study
otes: aStaff cots were obtained from the Lazzaro Spallanzani national institute for infectious diseases hospital. bPrice based on the national health system price list; Servizio
anitario Nazionale (SSN). CI stands for Confidence Intervals.
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well as treatment and follow-up, (further details on https://e-
detecttb.eu/ and described in reference Barcellini et al. (2019).
Collected data were automatically and securely transmitted to the
medical staff at the reference hospital. Cost data were collected
prospectively during the study period (2016-2017) including costs
of staff, transportation and the Xpert MTB/RIF Ultra test according
to the Servizio Sanitario Nazionale (SSN) (Table 1). Subsequently,
probabilities were calculated based on the screening pathway
(Barcellini et al., 2019). 3,787 individuals were screened, of which
891(24%) presented TB symptoms. Sputum samples were only
collected from 592 (63%) symptomatic participants. Among those
tested, 15 (3%) individuals were positive. A further 28 (1%) of 2,896
asymptomatic individuals were tested, among whom 3 (11%) were
positive. We assumed Xpert MTB/RIF Ultra sensitivity and
specificity of 0.85 (95%CI 0.82–0.88) and 0.98 (95%CI 0.96–0.98),
respectively based on a previous meta-analysis (Li et al., 2017).
Probability parameters used are summarized in Table 1. Therefore,
we undertook a cost-effectiveness analysis from program provider
perspective to assess the value for money of case finding by
estimating the cost per case of active TB detected. All analysis was
carried out using the Microsoft Excel software 2019 version.
Figure 1 summarizes the TB screening pathway using a
probabilistic decision tree based on the cost’s parameters (per
participant), and probabilities of each outcome obtained from the
EDETECT study described above. We assessed the cost-per test and
cost-per true-positive case, defined as total program cost divided
by the number of true positive TB diagnoses due to screening
program, compared with the status-quo of no intervention/
screening. The total cost of the program was s41,828.2, resulting
in an average cost per recruited patient of s11.05 (41,828/3,787),
while there were 15 cases diagnosed. Consequently, cost per true
positive case was s2,788.55. Furthermore, the total cost per single
TB positive diagnosis was s81.12 (1.09 + 62.08 + 17.95).
Early case detection is a cost-effective intervention in Italy given
the very low cost per true-positive case compared to other health
interventions (Woods et al., 2016; Dobler, 2016), and similar to
previous studies reporting between USD120 and USD23,660
(Dobler, 2016; Campbell et al., 2019; Zammarchi et al., 2015).
Furthermore, the cost per case detected is below the median
annual costs of TB per person at Italian hospitals (s8,509) in 2002
(Bocchino et al., 2006). Finally, our strategy could be even more
cost-effective if the early detection programme is adopted and the
samples are analysed locally avoiding having to incur in study costs
such as samples transportation to the study lab and questionnaire
administration which are not part of routine health expenditure.
The results are in line with the WHO guidelines for countries with
low TB incidence (Lönnroth et al., 2015) where active case finding
is crucial to reach the pre-elimination threshold (<10 TB cases per
million population) by 2035 (World Health Organization, 2014).
Furthermore, the development of a national plan to manage
migration-related issues (including testing for migrant specific
health risk factors) and improved surveillance and TB control and
surveillance at or near the point of arrival of migrants are part of
the core interventions for TB elimination in Italy (Blasi et al., 2017;
Ingrosso et al., 2014).
The analysis has some limitations. First, we have not accounted
for transmission using transmission dynamic modelling. Conse-
quently, the intervention may be even more cost effective. Second,
it is difficult to compare this intervention with a do-nothing
scenario as there are costs involved in further treatments if early
detection is not addressed. Third, the Gross Domestic Product
(GDP) based threshold is for Disability Adjusted Life Years (DALYs)
averted; however, the intervention is cost-effective when compar-
ing our cost per true-positive TB case with other studies. Fourth,
individuals were not followed-up to determine the long-term
implication of early-detection or failure to identify cases.
Nevertheless, the project presents a relatively simple way of
analysing the costs associated with each diagnostic result, focusing
public policy on a priority high risk population subgroup. The
project also suggests that using cartridge based molecular test on
spot (such as Xpert MTB/RIF Ultra), compared to culture, can be
delivered with minimal technical support avoiding further
additional costs. Future work on cost and cost-effectivenessFigure 1. Active TB screening decision tree schematic.











































L. Goscé, E. Girardi, K. Allel et al. International Journal of Infectious Diseases xxx (xxxx) xxx–xxx
G Model
IJID-5186; No. of Pages 5nalysis in this population should collect costs of hospital
dmissions and treatment regimens, and potentially also address
 societal perspective. Analysis should also investigate the
opulation level epidemiological impact screening using trans-
ission dynamic modelling to estimate the possible number of
econdary infections averted.
onclusions
Evidence-based interventions have a major role in reducing the
pread of tuberculosis among migrants (Dasgupta and Menzies,
005), and early detection ensures that potential transmission is
verted (Lin and Flynn, 2010). We have demonstrated the
mportance of active case finding for TB, especially in a country
ith high numbers of migrant arrivals from high TB risk settings
hich may be a good example to take for other similar European
ountries. Targeted post-arrival screening for active TB in such
ettings may provide the most cost-effective solution to TB in Italy.
oreover, further analyses are necessary to ascertain the most
ost-effective model for latent TB infections diagnosis and
reatment in this population group in Italy and in other European
ountries experiencing high rates of incoming migrants.
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